AstraZeneca Total Long Term Liabilities 2010-2024 | AZN

AstraZeneca total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
  • AstraZeneca total long term liabilities for the quarter ending June 30, 2024 were $36.176B, a 10.45% increase year-over-year.
  • AstraZeneca total long term liabilities for 2023 were $31.411B, a 5.19% decline from 2022.
  • AstraZeneca total long term liabilities for 2022 were $33.132B, a 23.8% decline from 2021.
  • AstraZeneca total long term liabilities for 2021 were $43.482B, a 41.25% increase from 2020.
AstraZeneca Annual Total Long Term Liabilities
(Millions of US $)
2023 $31,411
2022 $33,132
2021 $43,482
2020 $30,784
2019 $28,664
2018 $30,315
2017 $30,329
2016 $30,601
2015 $26,678
2014 $21,619
2013 $16,595
2012 $15,685
2011 $13,612
2010 $15,930
2009 $16,459
AstraZeneca Quarterly Total Long Term Liabilities
(Millions of US $)
2024-06-30 $36,176
2024-03-31 $35,891
2023-12-31 $31,411
2023-09-30 $30,277
2023-06-30 $32,752
2023-03-31 $36,016
2022-12-31 $33,132
2022-09-30 $34,181
2022-06-30 $38,813
2022-03-31 $41,174
2021-12-31 $43,482
2021-09-30 $43,660
2021-06-30 $35,726
2021-03-31 $28,967
2020-12-31 $30,784
2020-09-30 $31,552
2020-06-30 $28,088
2020-03-31 $27,952
2019-12-31 $28,664
2019-09-30 $30,461
2019-06-30 $30,784
2019-03-31 $30,770
2018-12-31 $30,315
2018-09-30 $32,658
2018-06-30 $29,871
2018-03-31 $30,544
2017-12-31 $30,329
2017-09-30 $34,677
2017-06-30 $34,050
2017-03-31 $30,751
2016-12-31 $30,601
2016-09-30 $32,928
2016-06-30 $34,694
2016-03-31 $31,749
2015-12-31 $26,678
2015-09-30 $20,714
2015-06-30 $20,720
2015-03-31 $20,987
2014-12-31 $21,619
2014-09-30 $19,874
2014-06-30 $20,165
2014-03-31 $20,400
2013-12-31 $16,595
2013-09-30 $15,999
2013-06-30 $15,378
2013-03-31 $15,979
2012-12-31 $15,685
2012-09-30 $16,065
2012-06-30 $14,355
2012-03-31 $13,248
2011-12-31 $13,612
2011-09-30 $13,765
2011-06-30 $15,753
2011-03-31 $15,971
2010-12-31 $15,930
2010-09-30 $17,226
2010-06-30 $16,078
2010-03-31 $16,193
2009-12-31 $16,459
2009-09-30 $17,230
2009-06-30 $17,115
2009-03-31 $16,937
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $199.957B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51